Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
106.1 USD | -0.15% | -0.76% | -3.65% |
04-29 | Abbott's Dissolving Stent Gets FDA Approval For Arteries Below the Knee | MT |
04-26 | Dexcom's profit beats estimates on strong glucose monitor demand | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.65% | 184B | |
-1.76% | 107B | |
-2.91% | 67.52B | |
+1.47% | 50.06B | |
+10.16% | 45.67B | |
+3.40% | 41B | |
+3.81% | 26.73B | |
+4.26% | 26.47B | |
+15.23% | 25.05B | |
-2.50% | 24.56B |
- Stock Market
- Equities
- ABT Stock
- News Abbott Laboratories
- Raymond James Adjusts Abbott Laboratories' Price Target to $117 from $135, Keeps Outperform Rating